Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review

Abstract

The pharmacokinetics of beta-lactam antibiotics in intensive care patients may be profoundly altered due to the dynamic, unpredictable pathophysiological changes that occur in critical illness. For many drugs, significant increases in the volume of distribution and/or variability in drug clearance are common. When "standard" beta-lactam doses are used, such pharmacokinetic changes can result in subtherapeutic plasma concentrations, treatment failure, and the development of antibiotic resistance. Emerging data support the use of beta-lactam therapeutic drug monitoring (TDM) and individualized dosing to ensure the achievement of pharmacodynamic targets associated with rapid bacterial killing and optimal clinical outcomes. The purpose of this work was to describe the pharmacokinetic variability of beta-lactams in the critically ill and to discuss the potential utility of TDM to optimize antibiotic therapy through a structured literature review of all relevant publications between 1946 and October 2011. Only a few studies have reported the utility of TDM as a tool to improve beta-lactam dosing in critically ill patients. Moreover, there is little agreement between studies on the pharmacodynamic targets required to optimize antibiotic therapy. The impact of TDM on important clinical outcomes also remains to be established. Whereas TDM may be theoretically rational, clinical studies to assess utility in the clinical setting are urgently required.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 118

1. 1.

   Roberts JA Norris R Paterson DL Martin JH Therapeutic drug monitoring of antimicrobialsBr J Clin Pharmacol2012 732736

   Not in our library10.1111/j.1365-2125.2011.04080.x

2. 2.

   van Lent-Evers NA Mathot RA Geus WP van Hout BA Vinks AA Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysisTher Drug Monit1999 216373

   Not in our library10.1097/00007691-199902000-00010

3. 3.

   Moise-Broder PA Forrest A Birmingham MC Schentag JJ Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsClin Pharmacokinet2004 43925942

   Not in our library10.2165/00003088-200443130-00005

4. 4.

   Ariano RE Nyhlen A Donnelly JP Sitar DS Harding GK Zelenitsky SA Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremiaAnn Pharmacother2005 393238

   Not in our library10.1345/aph.1e271

5. 5.

   Li C Du X Kuti JL Nicolau DP Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infectionsAntimicrob Agents Chemother2007 5117251730

   Not in our library10.1128/aac.00294-06

6. 6.

   Lodise TP Lomaestro B Drusano GL Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategyClin Infect Dis2007 44357363

   Not in our library10.1086/510590

7. 7.

   McKinnon PS Paladino JA Schentag JJ Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infectionsInt J Antimicrob Ag2008 31345351

   Not in our library10.1016/j.ijantimicag.2007.12.009

8. 8.

   Niemiec PW Allo MD Miller CF Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive careArch Surg1987 122207212

   Not in our library10.1001/archsurg.1987.01400140089012

9. 9.

   Dorman T Swoboda S Zarfeshenfard F Trentler B Lipsett PA Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading doseCritical Care Research Group. Surgery1998 1247378

   Not in our library

10. 10.

    Roos JF Lipman J Kirkpatrick CM Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteriaIntensive Care Med2007 33781788

    Not in our library10.1007/s00134-007-0573-7

11. 11.

    Joukhadar C Frossard M Mayer BX Brunner M Klein N Siostrzonek P Eichler HG Muller M Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shockCrit Care Med2001 29385391

    Not in our library10.1097/00003246-200102000-00030

12. 12.

    Erlandsson M Burman LG Cars O Gill H Nilsson LE Walther SM Hanberger H Prescription of antibiotic agents in Swedish intensive care units is empiric and preciseScand J Infect Dis2007 396369

    Not in our library10.1080/00365540600740504

13. 13.

    Roberts JA Using PK/PD to optimize antibiotic dosing for critically ill patientsCurr Pharmaceut Biotechnol2011 1220702079

    Not in our library10.2174/138920111798808329

14. 14.

    Mohr JF Wanger A Rex JH Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patientsDiagn Micr Infec Dis2004 48125130

    Not in our library10.1016/j.diagmicrobio.2003.09.010

15. 15.
    Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams · 2011

    No notice
16. 16.

    Scaglione F Can PK/PD be used in everyday clinical practiceInt J Antimicrob Ag2002 19349353

    Not in our library10.1016/s0924-8579(02)00020-1

17. 17.

    Roberts JA Hope WW Lipman J Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?Int J Antimicrob Agents2010 35419420

    Not in our library10.1016/j.ijantimicag.2010.01.022

18. 18.

    Lipman J Wallis SC Boots RJ Cefepime versus cefpirome: the importance of creatinine clearanceAnesth Analg2003 9711491154

    Not in our library10.1213/01.ane.0000077077.54084.b0

19. 19.

    Kieft H Hoepelman AI Knupp CA van Dijk A Branger JM Struyvenberg A Verhoef J Pharmacokinetics of cefepime in patients with the sepsis syndromeJ Antimicrob Chemother1993 32Suppl B117122

    Not in our library10.1093/jac/32.suppl_b.117

20. 20.
    Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock · 2010

    No notice
21. 21.

    Gomez CM Cordingly JJ Palazzo MG Altered pharmacokinetics of ceftazidime in critically ill patientsAntimicrob Agents Chemother1999 4317981802

    Not in our library10.1128/aac.43.7.1798

22. 22.

    Georges B Conil J-M Seguin T Ruiz S Minville V Cougot P Decun J-F Gonzalez H Houin G Fourcade O Saivin S Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admissionAntimicrob Agents Chemother2009 5344834489

    Not in our library10.1128/aac.00430-09

23. 23.

    Douglas A Udy AA Wallis SC Jarrett P Stuart J Lassig-Smith M Deans R Roberts MS Taraporewalla K Jenkins J Medley G Lipman J Roberts JA Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semi-elective abdominal aortic aneurysm open repair surgeryAntimicrob Agents Chemother2011 5552385242

    Not in our library10.1128/aac.05033-11

24. 24.

    Roberts JA Kirkpatrick CMJ Roberts MS Dalley AJ Lipman J First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsisInt J Antimicrob Ag2010 35156163

    Not in our library10.1016/j.ijantimicag.2009.10.008

25. 25.

    Garot D Respaud R Lanotte P Simon N Mercier E Ehrmann S Perrotin D Dequin PF Le Guellec C Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisalBr J Clin Pharmacol2011 72758767

    Not in our library10.1111/j.1365-2125.2011.04005.x

26. 26.

    Brink AJ Richards GA Schillack V Kiem S Schentag J Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsisInt J Antimicrob Ag2009 33432436

    Not in our library10.1016/j.ijantimicag.2008.10.005

27. 27.

    Ulldemolins M Roberts JA Wallis SC Rello J Lipman J Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokineticsJ Antimicrob Chemother2010 6517711778

    Not in our library10.1093/jac/dkq184

28. 28.

    Van Dalen R Vree TB Baars IM Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patientsPharm Weekbl Sci1987 998103

    Not in our library10.1007/bf01960743

29. 29.

    Moon YS Chung KC Gill MA Pharmacokinetics of meropenem in animals, healthy volunteers, and patientsClin Infect Dis1997 24Suppl 2S249S255

    Not in our library10.1093/clinids/24.supplement_2.s249

30. 30.

    Joynt GM Lipman J Gomersall CD Young RJ Wong EL Gin T The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patientsJ Antimicrob Chemother2001 47421429

    Not in our library10.1093/jac/47.4.421

31. 31.

    Udy AA Putt MT Shanmugathasan S Roberts JA Lipman J Augmented renal clearance in the Intensive Care Unit: an illustrative case seriesInt J Antimicrob Ag2010 35606608

    Not in our library10.1016/j.ijantimicag.2010.02.013

32. 32.

    Burkhardt O Kumar V Katterwe D Majcher-Peszynska J Drewelow B Derendorf H Welte T Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentrationJ Antimicrob Chemother2007 59277284

    Not in our library10.1093/jac/dkl485

33. 33.

    Lipman J Wallis SC Rickard C Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosingAntimicrob Agents Chemother1999 4325592561

    Not in our library10.1128/aac.43.10.2559

34. 34.

    Delattre IK Musuamba FT Verbeeck RK Dugernier T Spapen H Laterre P-F Wittebole X Cumps J Taccone FS Vincent J-L Jacobs F Wallemacq PE Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacinClin Biochem2010 43589598

    Not in our library10.1016/j.clinbiochem.2009.12.007

35. 35.

    Benko AS Cappelletty DM Kruse JA Rybak MJ Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsAntimicrob Agents Chemother1996 40691695

    Not in our library10.1128/aac.40.3.691

36. 36.

    Young RJ Lipman J Gin T Gomersall CD Joynt GM Oh TE Intermittent bolus dosing of ceftazidime in critically ill patientsJ Antimicrob Chemother1997 40269273

    Not in our library10.1093/jac/40.2.269

37. 37.

    Thalhammer F Traunmuller F El Menyawi I Frass M Hollenstein UM Locker GJ Stoiser B Staudinger T Thalhammer-Scherrer R Burgmann H Continuous infusion versus intermittent administration of meropenem in critically ill patientsJ Antimicrob Chemother1999 43523527

    Not in our library10.1093/jac/43.4.523

38. 38.

    Novelli A Adembri C Livi P Fallani S Mazzei T De Gaudio AR Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsisClin Pharmacokinet2005 44539549

    Not in our library10.2165/00003088-200544050-00007

39. 39.

    Burkhardt O Derendorf H Welte T Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practiceExpert Opin Pharmacother2007 8237256

    Not in our library10.1517/14656566.8.2.237

40. 40.

    Boselli E Breilh D Saux M-C Gordien J-B Allaouchiche B Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumoniaIntens Care Med2006 3220592062

    Not in our library10.1007/s00134-006-0401-5

41. 41.

    Burgess DS Frei CR Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamicsJ Antimicrob Chemother2005 56893898

    Not in our library10.1093/jac/dki335

42. 42.

    Tam VH Louie A Lomaestro BM Drusano GL Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosaPharmacotherapy2003 23291295

    Not in our library10.1592/phco.23.3.291.32110

43. 43.

    DeRyke CA Kuti JL Nicolau DP Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004Pharmacotherapy2007 27333342

    Not in our library10.1592/phco.27.3.333

44. 44.

    Zelenitsky SA Ariano RE Zhanel GG Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance dataJ Antimicrob Chemother2011 66343349

    Not in our library10.1093/jac/dkq348

45. 45.

    Aubert G Carricajo A Coudrot M Guyomarc’h S Auboyer C Zeni F Prospective determination of serum ceftazidime concentrations in intensive care unitsTher Drug Monit2010 32517519

    Not in our library10.1097/ftd.0b013e3181e60ca6

46. 46.

    Hallam MJ Allen JM James SE Donaldson PMW Davies JG Hanlon GW Dheansa BS Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsisJ Burn Care Res2010 31207209

    Not in our library10.1097/bcr.0b013e3181c89ee3

47. 47.

    Burkhardt O Kumar V Schmidt S Kielstein JT Welte T Derendorf H Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulationsInt J Antimicrob Agents2010 359697

    Not in our library10.1016/j.ijantimicag.2009.09.007

48. 48.

    Boyadjiev I Boulamery A Simon N Martin C Bruguerolle B Leone M Penetration of Ertapenem into Muscle Measured by In Vivo Microdialysis in Mechanically Ventilated PatientsAntimicrob Agents Ch2011 5535733575

    Not in our library10.1128/aac.00180-11

49. 49.

    Chapuis TM Giannoni E Majcherczyk PA Chiolero R Schaller M-D Berger MM Bolay S Decosterd LA Bugnon D Moreillon P Prospective monitoring of cefepime in intensive care unit adult patientsCrit Care2010 14R51

    Not in our library10.1186/cc8941

50. 50.
    A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit

    Not checked
51. 51.

    Craig WA Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis1998 26110quiz 11–12

    Not in our library10.1086/516284

52. 52.

    Vogelman B Gudmundsson S Leggett J Turnidge J Ebert S Craig WA Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal ModelJ Infect Dis1988 158831847

    Not in our library10.1093/infdis/158.4.831

53. 53.

    Turnidge JD The pharmacodynamics of beta-lactamsClin Infect Dis1998 271022

    Not in our library10.1086/514622

54. 54.

    Alou L Aguilar L Sevillano D Gimenez M-J Echeverria O Gomez-Lus M-L Prieto J Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic modelJ Antimicrob Chemother2005 55209213

    Not in our library10.1093/jac/dkh536

55. 55.

    Buijk SLCE Gyssens IC Mouton JW Van Vliet A Verbrugh HA Bruining HA Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infectionsJ Antimicrob Chemother2002 49121128

    Not in our library10.1093/jac/49.1.121

56. 56.

    Lipman J Gomersall CD Gin T Joynt GM Young RJ Continuous infusion ceftazidime in intensive care: a randomized controlled trialJ Antimicrob Chemother1999 43309311

    Not in our library10.1093/jac/43.2.309

57. 57.

    Nicolau DP Lacy MK McNabb JC Quintiliani R Nightingale CH Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumoniaInfect Dis Clin Prac1999 84549

    Not in our library10.1097/00019048-199901000-00009

58. 58.

    Nicolau DP McNabb J Lacy MK Quintiliani R Nightingale CH Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumoniaInt J Antimicrob Ag2001 17497504

    Not in our library10.1016/s0924-8579(01)00329-6

59. 59.

    Nicolau DP McNabb JC Lacy MK Li J Quintiliani R Nightingale CH Pharmacokinetics and pharmacodynamics of continuous and intermittent ceftazidime during the treatment of nosocomial pneumoniaClin Drug Invest1999 18133139

    Not in our library10.2165/00044011-199918020-00006

60. 60.

    Roberts JA Webb S Paterson D Ho KM Lipman J A systematic review on clinical benefits of continuous administration of beta-lactam antibioticsCrit Care Med2009 3720712078

    Not in our library10.1097/ccm.0b013e3181a0054d

61. 61.

    Roberts JA Roberts MS Robertson TA Dalley AJ Lipman J Piperacillin penetration into tissue of critically ill patients with sepsis–bolus versus continuous administration?Crit Care Med2009 37926933

    Not in our library10.1097/ccm.0b013e3181968e44

62. 62.

    Roberts JA Kirkpatrick CMJ Roberts MS Robertson TA Dalley AJ Lipman J Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distributionJ Antimicrob Chemother2009 64142150

    Not in our library10.1093/jac/dkp139

63. 63.

    Abanades S Nolla J Rodriguez-Campello A Pedro C Valls A Farre M Reversible coma secondary to cefepime neurotoxicityAnn Pharmacother2004 38606608

    Not in our library10.1345/aph.1d322

64. 64.

    Bresson J Paugam-Burtz C Josserand J Bardin C Mantz J Pease S Cefepime overdosage with neurotoxicity recovered by high-volume haemofiltrationJ Antimicrob Chemother2008 62849850

    Not in our library10.1093/jac/dkn256

65. 65.

    Dakdouki GK Al-Awar GN Cefepime-induced encephalopathyInt J Infect Dis2004 85961

    Not in our library10.1016/j.ijid.2003.09.003

66. 66.

    Malone RS Fish DN Abraham E Teitelbaum I Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patientsAntimicrob Agents Chemother2001 4531483155

    Not in our library10.1128/aac.45.11.3148-3155.2001

67. 67.

    Isla A Gascon AR Maynar J Arzuaga A Toral D Pedraz JL Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patientsClin Ther2005 27599608

    Not in our library10.1016/j.clinthera.2005.05.004

68. 68.

    Allaouchiche B Breilh D Jaumain H Gaillard B Renard S Saux MC Pharmacokinetics of cefepime during continuous venovenous hemodiafiltrationAntimicrob Agents Chemother1997 4124242427

    Not in our library10.1128/aac.41.11.2424

69. 69.

    Mariat C Venet C Jehl F Mwewa S Lazarevic V Diconne E Fonsale N Carricajo A Guyomarc’h S Vermesch R Aubert G Bidault R Bertrand J-C Zeni F Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendationCrit Care2006 10R26

    Not in our library10.1186/cc3993

70. 70.

    Traunmuller F Schenk P Mittermeyer C Thalhammer-Scherrer R Ratheiser K Thalhammer F Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patientsJ Antimicrob Chemother2002 49129134

    Not in our library10.1093/jac/49.1.129

71. 71.

    Krueger WA Neeser G Schuster H Schroeder TH Hoffmann E Heininger A Dieterich H-J Forst H Unertl KE Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltrationChemotherapy2003 49280286

    Not in our library10.1159/000074527

72. 72.

    Tegeder I Neumann F Bremer F Brune K Lotsch J Geisslinger G Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltrationClin Pharmacol Ther1999 655057

    Not in our library10.1016/s0009-9236(99)70121-9

73. 73.

    Bilgrami I Roberts JA Wallis SC Thomas J Davis J Fowler S Goldrick PB Lipman J Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltrationAntimicrob Agents Chemother2010 5429742978

    Not in our library10.1128/aac.01582-09

74. 74.

    Keller E Bohler J Busse-Grawitz A Reetze-Bonorden P Krumme B Schollmeyer P Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patientsClin Nephrol1995 43Suppl 1S20S23

    Not in our library

75. 75.

    Arzuaga A Maynar J Gascon AR Isla A Corral E Fonseca F Sanchez-Izquierdo JA Rello J Canut A Pedraz JL Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltrationJ Clin Pharmacol2005 45168176

    Not in our library10.1177/0091270004269796

76. 76.

    Matzke GR Frye RF Joy MS Palevsky PM Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysisPharmacotherapy2000 20635643

    Not in our library10.1592/phco.20.7.635.35170

77. 77.

    Kroh UF Lennartz H Edwards DJ Stoeckel K Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltrationJ Clin Pharmacol1996 3611141119

    Not in our library10.1002/j.1552-4604.1996.tb04164.x

78. 78.

    Bouman CSC van Kan HJM Koopmans RP Korevaar JC Schultz MJ Vroom MB Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosingIntens Care Med2006 3220132019

    Not in our library10.1007/s00134-006-0397-x

79. 79.

    Meyer B el GS A Delle KG Locker GJ Heinz G Jaeger W Thalhammer F How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillinKidney Blood Press Res2003 26135140

    Not in our library10.1159/000070997

80. 80.

    Choi G Gomersall CD Tian Q Joynt GM Freebairn R Lipman J Principles of antibacterial dosing in continuous renal replacement therapyCrit Care Med2009 3722682282

    Not in our library10.1097/ccm.0b013e3181aab3d0

81. 81.

    Schetz M Ferdinande P Van den Berghe G Verwaest C Lauwers P Pharmacokinetics of continuous renal replacement therapyIntensive Care Med1995 21612620

    Not in our library10.1007/bf01700172

82. 82.

    Isla A Gascon AR Maynar J Arzuaga A Sanchez-Izquierdo JA Pedraz JL In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapiesChemotherapy2007 53194201

    Not in our library10.1159/000100864

83. 83.

    Isla A Maynar J Sanchez-Izquierdo JA Gascon AR Arzuaga A Corral E Pedraz JL Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patientsJ Clin Pharmacol2005 4512941304

    Not in our library10.1177/0091270005280583

84. 84.
    Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy · 2011

    No notice
85. 85.

    Grill MF Maganti RK Neurotoxic effects associated with antibiotic use: management considerationsBrit J Clin Pharmaco2011 72381393

    Not in our library10.1111/j.1365-2125.2011.03991.x

86. 86.

    Giles LJ Jennings AC Thomson AH Creed G Beale RJ McLuckie A Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltrationCrit Care Med2000 28632637

    Not in our library10.1097/00003246-200003000-00005

87. 87.

    Robatel C Decosterd LA Biollaz J Eckert P Schaller MD Buclin T Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patientsJ Clin Pharmacol2003 4313291340

    Not in our library10.1177/0091270003260286

88. 88.

    Ververs TF van Dijk A Vinks SA Blankestijn PJ Savelkoul JF Meulenbelt J Boereboom FT Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltrationCrit Care Med2000 2834123416

    Not in our library10.1097/00003246-200010000-00006

89. 89.

    Thalhammer F Schenk P Burgmann H El Menyawi I Hollenstein UM Rosenkranz AR Sunder-Plassmann G Breyer S Ratheiser K Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltrationAntimicrob Agents Chemother1998 4224172420

    Not in our library10.1128/aac.42.9.2417

90. 90.

    Valtonen M Tiula E Takkunen O Backman JT Neuvonen PJ Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failureJ Antimicrob Chemother2001 48881885

    Not in our library10.1093/jac/48.6.881

91. 91.

    Mueller SC Majcher-Peszynska J Hickstein H Francke A Pertschy A Schulz M Mundkowski R Drewelow B Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysisAntimicrob Agents Chemother2002 4615571560

    Not in our library10.1128/aac.46.5.1557-1560.2002

92. 92.

    Dasgupta A Therapeutic Drug Monitoring I, Dasgupta AHandbook of Drug Monitoring MethodsIntroduction to Therapeutic Drug Monitoring2008 New Jersey: Humana Press Inc139

    Not in our library

93. 93.

    Dasgupta A Dasgupta AAdvances in Chromatographic Techniques for Therapeutic Drug MonitoringIntroduction to Therapeutic Drug Monitoring and Chromatography2010 Boca Raton: CRC Press Taylor and Francis Group, LLC138

    Not in our library

94. 94.

    Lam S Gomolin IH Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature reviewPharmacotherapy2006 2611691174

    Not in our library10.1592/phco.26.8.1169

95. 95.

    Ye R-H Lin M-Y Sung C-C Lin S-H Standard Dose of Piperacillin Induced Neurotoxicity in Advanced Renal FailureActa Nephrologica2011 258992

    Not in our library

96. 96.

    Huang W-T Hsu Y-J Chu P-L Lin S-H Neurotoxicity Associated with Standard Doses of Piperacillin in an Elderly Patient with Renal FailureInfection2009 37374376

    Not in our library10.1007/s15010-009-8373-3

97. 97.

    Chow KM Hui AC Szeto CC Neurotoxicity induced by beta-lactam antibiotics: from bench to bedsideEur J Clin Microbiol Infect Dis2005 24649653

    Not in our library10.1007/s10096-005-0021-y

98. 98.

    Conil J-M Georges B Mimoz O Dieye E Ruiz S Cougot P Samii K Houin G Saivin S Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patientsIntens Care Med2006 3220632066

    Not in our library10.1007/s00134-006-0421-1

99. 99.

    Roberts JA Ulldemolins M Roberts MS McWhinney B Ungerer J Paterson DL Lipman J Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of conceptInt J Antimicrob Ag2010 36332339

    Not in our library10.1016/j.ijantimicag.2010.06.008

100. 100.

     Blondiaux N Wallet F Favory R Onimus T Nseir S Courcol RJ Durocher A Roussel-Delvallez M Daily serum piperacillin monitoring is advisable in critically ill patientsInt J Antimicrob Agents2010 35500503

     Not in our library10.1016/j.ijantimicag.2010.01.018

101. 101.

     Pea F Cojutti P Sbrojavacca R Cadeo B Cristini F Bulfoni A Furlanut M TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patientAnn Pharmacother2011 45e37

     Not in our library10.1345/aph.1p745

102. 102.

     Taccone FS Cotton F Roisin S Vincent JL Jacobs F Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shockAntimicrob Agents Ch2012 5621292131

     Not in our library10.1128/aac.06389-11

103. 103.

     Patel BM Paratz J See NC Muller MJ Rudd M Paterson D Briscoe SE Ungerer J McWhinney BC Lipman J Roberts JA Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patients-A One-Year Prospective StudyTher Drug Monit2012 34160164

     Not in our library10.1097/ftd.0b013e31824981a6

104. 104.

     Connor MJ Salem C Bauer SR Hofmann CL Groszek J Butler R Rehm SJ Fissell WH Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysisAntimicrob Agents Chemother2011 55557560

     Not in our library10.1128/aac.00548-10

105. 105.

     Craig WA Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporinsDiagn Microbiol Infect Dis1995 228996

     Not in our library10.1016/0732-8893(95)00053-d

106. 106.

     Drusano GL Prevention of resistance: a goal for dose selection for antimicrobial agentsClin Infect Dis2003 36S42S50

     Not in our library10.1086/344653

107. 107.

     Mouton JW den Hollander JG Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic modelAntimicrob Agents Chemother1994 38931936

     Not in our library10.1128/aac.38.5.931

108. 108.

     Tam VH Schilling AN Neshat S Poole K Melnick DA Coyle EA Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosaAntimicrob Agents Chemother2005 4949204927

     Not in our library10.1128/aac.49.12.4920-4927.2005

109. 109.

     Roberts JA Lipman J Pharmacokinetic issues for antibiotics in the critically ill patientCrit Care Med2009 37840851quiz 859

     Not in our library10.1097/ccm.0b013e3181961bff

110. 110.

     Verdier MC Tribut O Tattevin P Le Tulzo Y Michelet C Bentue-Ferrer D Simultaneous determination of 12 beta-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoringAntimicrob Agents Chemother2011 5548734879

     Not in our library10.1128/aac.00533-11

111. 111.

     McWhinney BC Wallis SC Hillister T Roberts JA Lipman J Ungerer JP Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detectionJ Chromatogr B Analyt Technol Biomed Life Sci2010 87820392043

     Not in our library10.1016/j.jchromb.2010.05.027

112. 112.

     Morris RG Tett SE Ray JE Cyclosporin A monitoring in Australia: consensus recommendationsTher Drug Monit1994 16570576

     Not in our library10.1097/00007691-199412000-00007

113. 113.

     Ahrer W Scherwenk E Buchberger W Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometryJ Chromatogr A2001 9106978

     Not in our library10.1016/s0021-9673(00)01187-0

114. 114.

     Van Emon JM LG C Environmental monitoring and human exposure assessment using immunochemical techniquesJ Microbiol Methods1998 32121131

     Not in our library10.1016/s0167-7012(98)00019-0

115. 115.

     Norris RL Martin JH Thompson E Ray JE Fullinfaw RO Joyce D Barras M Jones GR Morris RG Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional developmentTher Drug Monit2010 32615623

     Not in our library10.1097/ftd.0b013e3181ea3e8a

116. 116.

     Smith PF Petros WP Soucie MP Copeland KR New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal diseaseTher Drug Monit1998 20231235

     Not in our library10.1097/00007691-199804000-00016

117. 117.

     Benito-Pena E Moreno-Bondi MC Orellana G Maquieira A van Amerongen A Development of a novel and automated fluorescent immunoassay for the analysis of beta-lactam antibioticsJ Agric Food Chem2005 5366356642

     Not in our library10.1021/jf0511502

118. 118.

     Usleber E Litz S Martlbauer E Production and characterization of group-specific antibodies against penicillin antibioticsFood Agric Immunol1998 10317324

     Not in our library10.1080/09540109809354995

Cited by papers we hold 5

• The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance · 2021
  No notice
• Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy · 2020
  Not checked
• Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation—SFAR) · 2019
  No notice
• Meropenem pharmacokinetics in children: series of cases · 2018
  Not checked
• Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases · 2016
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.